Coto Biostrical Strategy cooperation Jiang Chinese medicine industry, layout of intestinal health products innovation and research and development.

, August 29, 2020, at the 2020 Intestinal Health Summit Forum, Koto Bio (300858. SZ) and Jiang Chinese Medicine (600750.SH) signed the Strategic Cooperation Agreement, Coto Bio will play in the bacteria resources, strain screening and processing technology, probiotic evaluation technology and other advantages, United Jiang Chinese Medicine in brand promotion, preparation technology, health food, drug development and other advantages, through strong joint and complementary advantages, jointly promote intestinal health research and intestinal health product development of a full range of strategic cooperation.is the leading probiotic lactic acid bacteria industry chain high-tech enterprises, committed to the basic research of national probiotic technology, applied research and industrialization. The company was listed on the Shenzhen Stock Exchange GEM on July 27, 2020, as the "first stock" of the probiotic industry, listed just "full moon", that is, "hand in hand" Jiang traditional Chinese medicine industry, highlighting the fast pace and hard strength of this national probiotic industry leader."signature" strains Koto bios was founded immediately after the launch of the species program, along the ancient trade routes and fermented milk transmission channels carried out a global collection, separation and protection of species, aimed at collecting and protecting lactic acid bacteria resources, the plan Since its inception, more than 20,000 strains of lactic acid bacteria (including probiotics) have been isolated, collected and preservationed from natural fermented food, baby faeces and breast milk collected from the original pollution-free areas, making it the largest resource bank for lactic acid bacteria in China and even Asia.The establishment ofspecies bank provides valuable probiotic resources for Koto organisms, through the excavation of the species bank, Coto biology screened out a series of star strains:cheese lactobacillus Zhang: isolated from the natural fermented acid horse milk in the Xilin Guole prairie, after separation of the strain was genome sequencing, becoming the first in China Lactic acid bacteria that have completed genome-wide sequencing, filed 16 patents for inventions and published more than 170 papers around the strain, and the strain has been found to have many benefits in a series of studies and has been widely used in a variety of products, both as a "signature" strain of Koto Biology and as a representative of the Chinese strain of the internationally renowned strain of The Biske.Milk Bifidobacteria V9: isolated from the intestines of healthy Mongolian children, applied for 20 invention patents around the strain, published 33 papers, found that the bacteria or to prevent and improve constipation, irritable bowel syndrome and inflammatory bowel disease has a certain role.Plant Lactobacillus P-8: isolated from the natural fermentation of sour cow's milk in Urat, Bayangar City, Inner Mongolia, applied for 11 patents, published 62 papers, found that the strain or has improved lipid metabolism, reduce blood lipids, improve the body's antioxidant capacity and other effects.Probio-M8 and Lactobacillus Saccharide probio-M9: isolated from breast milk in healthy women, have been studied and transformed by industry.Built in China After more than ten years of scientific and technological investment and industrial upgrading, Koto Bio has established a research platform for lactic acid bacteria resource collection and biodiversity, a research platform for probiotics and gut bacteri and metabolomics, a pilot platform for lactic acid bacteria fermentation technology and its application. The invention of precision nutrition of probiotic lactic acid bacteria high-density fermentation technology, micro-enculated high-efficiency protection of probiotic lactic acid bacteria freeze-drying technology, formed from the species screening, functional research, bacterial powder production, product application to clinical verification of a complete set of technical processes.The company has built a modern bacteria production plant and international advanced bacteria powder and preparation intelligent manufacturing production system, in Beijing, Jinhua, Qingdao, Hohhot layout of the four major industrial bases, product coverage of food, animal nutrition, health care, agricultural bacteria fertilizer, biological disease resistance and other fields, while actively through extensive clinical experiments, explore the application of probiotics in the field of medicine. In 2017, the company's probiotics became the only micro-ecological preparation protection products for athletes of the Training Bureau of the State Sports Administration, providing intestinal health protection to 1,200 athletes from 14 national teams.ChinaHaskto Bio has a team of more than 30 Ph.D.s and master's degrees in high-water technology. In addition, renowned scientists such as Chen Wei, President of Jiangnan University, Professor Yang Ruixuan of the National Key Laboratory of Pathogenic Microbiology of the Institute of Microbiology of the Academy of Military Medical Sciences, Professor Li Victory of the School of Animal Science and Technology of the Agricultural University of China, and Li Yuankun, Professor of Microbiology at Yang Yanning School of Medicine of the National University of Singapore, were invited to become external think tanks, fully assisting enterprise development.Relying on internal and external wisdom, combined with its own innovation needs, Koto Bio has been active in probiotic basic research and product development in recent years:launched the Chinese Intestinal Microbiological System Research Project in 2018, which includes the establishment ofChinese The unique intestinal bacteria database and intestinal bacteria based on species/subseed levels study the relationship between probiotics, specific intestinal bacterial structures and health and disease, screen for new probiotics for precise intervention, and customize personalized probiotics.conducted more than 30 clinical trials of its star strains to explore the effects of probiotics on different diseases such as stomach ulcers, type 2 diabetes, osteoporosis, Parkinson's disease, and irritable bowel syndrome. In clinical studies, its C. D. V9 demonstrated potentially improved effects on diseases such as IBS/IBD, constipation, and diarrhea;strong combination to help China's intestinal industry development This 2020 intestinal health summit forum, Coto Bio and Jiang traditional Chinese medicine industry are representatives of domestic industries in the field of enterprises, the two companies set up a strategic alliance, reflecting the joint layout of the intestinal health industry, seize the development opportunities of the industry strategic intent. Jiang Traditional Chinese Medicine, as a large-scale pharmaceutical listed company, is committed to gastrointestinal health for 50 years, for many years leading the development of China's OTC throat, digestion, intestinal conditioning market. It is believed that through the establishment of cooperative relations, the two sides will accelerate the sharing of resources and complement each other's advantages, and help and empower China's intestinal health research and the rapid development of the intestinal health industry. According to Euromonitor statistics and projections, the market size of probiotic products (including probiotic supplements, probiotic beverages, probiotic yogurt, etc.) in China will be about 45.5 billion yuan in 2017 and is expected to grow to 89.6 billion yuan by 2022. With the implementation of the "Healthy China 2030" program outline, the country is vigorously promoting the development of the health industry, and the new crown pneumonia epidemic also let people more scientifically examine health issues, which undoubtedly for the development of probiotic health products market has brought unprecedented opportunities. We also believe that enterprises in the probiotic industry, represented by Coto Bio, adhere to science and evidence-based guidance, strengthen scientific and technological innovation and quality control, enhance brand, marketing, China's probiotic market and intestinal industry will certainly flourish. .